A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis

References

• Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987–2019. N Engl J Med. 2020;382(16):1567–1568.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and n-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–3757.
   PubMed Web of Science ®Google Scholar
• Manwani R, Sharpley F, Mahmood S, et al. Achieving a difference in involved and uninvolved light chains (dflc) of less than 10mg/l is the new goal of therapy in systemic AL amyloidosis: analysis of 916 patients treated upfront with bortezomib-based therapy. Blood. 2018;132(Supplement 1):3262–3262.
   Google Scholar
• Godara A, Toskic D, Rosenthal B, et al. In systemic light-chain amyloidosis complete and very good partial responses are not enough: involved free light chain (iFLC) levels < 10mg/L are associated with optimal long-term survival. Blood. 2019;134(Supplement_1):4369–4369.
   Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317–2325.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–4549.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031–1037.
   PubMed Web of Science ®Google Scholar
• Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–615.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Palladini G, Minnema MC, ANDROMEDA Trial Investigators, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46–58.
   PubMed Web of Science ®Google Scholar
• Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271–2280.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327–1337.
   PubMed Web of Science ®Google Scholar
• Manwani R, Mahmood S, Sachchithanantham S, et al. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. Br J Haematol. 2019;187(5):638–641.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Scott EC, Liedtke M, et al. A Phase i dose-escalation study of carfilzomib in patients with previously-treated systemic light-chain (AL) amyloidosis. Blood. 2014;124(21):4741–4741.
   Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol. 2005;79(4):319–328.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, ASPIRE Investigators, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38(28):3252–3260.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Landau H, Scott EC, et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Blood. 2016;128(22):645–645.
   Web of Science ®Google Scholar
• Waxman AJ, Clasen S, Hwang W-T, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):e174519–e174519.
   PubMed Web of Science ®Google Scholar
• Shah C, Bishnoi R, Jain A, et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma. 2018;59(11):2557–2569.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71–80.
   PubMed Web of Science ®Google Scholar
• Efstathios Kastritis GP, Minnema MC, et al. Subcutaneous Daratumumab + Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in patients with newly diagnosed light chains (AL) amyloidosis: primary results from the phase 3 ANDROMEDA study. Conference Paper presented at: EHA 25 Virtual 2020.
   Google Scholar